LB-102

“In 2021, there were approximately 23.2 million individuals worldwide living with schizophrenia (~0.3% of the global population). The worldwide age-standardized prevalence rate was 277.7 per 100 000 (95% UI = 229.8-329.1), and the crude rate was 293.8 per 100 000 individuals (95% UI = 243.4-347.5). Crude prevalence rates were highest among individuals ages 35-39 for both sexes as compared to all other age groups.” (opens the source at this quote in a new tab)CopyFlag

“The global age-standardized point prevalence of schizophrenia in 2016 was estimated to be 0.28% (95% uncertainty interval [UI]: 0.24–0.31). No sex differences were observed in prevalence. Age-standardized point prevalence rates did not vary widely across countries or regions. Globally, prevalent cases rose from 13.1 (95% UI: 11.6–14.8) million in 1990 to 20.9 (95% UI: 18.5–23.4) million cases in 2016.” (opens the source at this quote in a new tab)CopyFlag

“Schizophrenia affects approximately 1 in 300 (0.29% or 27 million) people worldwide, rising to 1 in 206 people (0.49%) among adults aged 20 and over” (opens the source at this quote in a new tab)CopyFlag

“The median values per 1,000 persons (10%–90% quantiles) for the distributions for point, period, lifetime, and lifetime morbid risk were 4.6 (1.9–10.0), 3.3 (1.3–8.2), 4.0 (1.6–12.1), and 7.2 (3.1–27.1), respectively. Based on combined prevalence estimates, we found no significant difference (a) between males and females, or (b) between urban, rural, and mixed sites.” (opens the source at this quote in a new tab)CopyFlag

“Among 21 studies reporting 12-month prevalence, the median estimate was 0.33 % with an interquartile range (IQR) of 0.26 %–0.51 %. The median estimate of lifetime prevalence among 29 studies was 0.48 % (IQR: 0.34 %–0.85 %).” (opens the source at this quote in a new tab)CopyFlag

“Across these studies, the pooled median point and 12-month prevalence for persons was 3.89 and 4.03 per 1000 respectively; and the median lifetime prevalence was 7.49 per 1000.” (opens the source at this quote in a new tab)CopyFlag

“The lifetime prevalence of schizophrenia is estimated to be approximately 0.7% (McGrath et al. 2008; Moreno-Küstner et al. 2018; van der Werf et al. 2014), although findings vary depending on the study location, demographic characteristics of the sample, the approach used for case-finding, the method used for diagnostic confirmation, and the diagnostic criteria used.” (opens the source at this quote in a new tab)CopyFlag

“Across studies that use household-based survey samples, clinical diagnostic interviews, and medical records, estimates of the prevalence of schizophrenia and related psychotic disorders in the U.S. range between 0.25% and 0.64%.” (opens the source at this quote in a new tab)CopyFlag

“The Mental and Substance Use Disorders Prevalence Study (MDPS) was conducted between October 2020 and October 2022. Interviewers administered a structured clinical interview for the DSM-5 (N=5,679 participants; N=4,764 in households).” (opens the source at this quote in a new tab)CopyFlag

“The prevalence estimates of lifetime and past-year schizophrenia spectrum disorders were 1.8% (95% CI=1.3%–2.5%) and 1.2% (95% CI=0.9%–1.8%), respectively.” (opens the source at this quote in a new tab)CopyFlag

“The prevalence rates of lifetime and past-year schizophrenia spectrum disorders were two to four times higher than previously reported.” (opens the source at this quote in a new tab)CopyFlag

“The study provides prevalence rates of mental and substance use disorders including past-year and lifetime schizophrenia spectrum disorders (defined as including schizophrenia, schizoaffective disorder, and schizophreniform disorder)” (opens the source at this quote in a new tab)CopyFlag

“The study sample included adults aged 18 to 65 residing in households, prisons, homeless shelters, and state psychiatric hospitals in the United States.” (opens the source at this quote in a new tab)CopyFlag

“Approximately 3.7 million adults aged 18 to 65 (1.8 percent) had a lifetime history of schizophrenia spectrum disorders. A total of 1.2 percent of adults aged 18 to 65 (approximately 2.5 million adults) met diagnostic criteria for a schizophrenia spectrum disorder in the past year.” (opens the source at this quote in a new tab)CopyFlag

“The MI prevalence estimate of NAP (standard error in parentheses) is 3.1 (1.5) per 1000 population lifetime and 1.4 (1.0) per 1000 past 12 months.” (opens the source at this quote in a new tab)CopyFlag

“The 12-month prevalence of diagnosed schizophrenia in the USA in 2002 was estimated at 5.1 per 1000 lives. The Medicaid population was identified with the highest prevalence rate among the populations studied.” (opens the source at this quote in a new tab)CopyFlag

“Per 100,000 people, the weighted prevalence of schizophrenia in the United States was an estimated 448.5, according to the study.” (opens the source at this quote in a new tab)CopyFlag

“By payer type, the highest prevalence of schizophrenia was among patients with Medicare Advantage, followed by Medicaid Fee-for-Service and Medicaid.” (opens the source at this quote in a new tab)CopyFlag

“The prevalence of schizophrenia in the total population was higher in Medicaid (2.13%, 95% CI: 2.12–2.15; n = 94,153 of 4,414,153) than in MarketScan (0.134%, 95% CI: 0.132–0.135; n = 21,963 of 16,365,997).” (opens the source at this quote in a new tab)CopyFlag

“In addition, prevalence increased over the lifespan in the Medicaid population, but decreased in the employment based MarketScan database beginning in early adulthood.” (opens the source at this quote in a new tab)CopyFlag

“Estimates of the prevalence of schizophrenia in the United States vary from 0.3 to 1.6% in community-based samples, 1.02% in uninsured samples, and 0.13% in commercial insurance samples to 1.66–5.11% in Medicaid” (opens the source at this quote in a new tab)CopyFlag

“Schizophrenia prevalence was 0.11% and 0.99% in commercially and Medicaid-insured patients, respectively.” (opens the source at this quote in a new tab)CopyFlag

“Annual prevalence of schizophrenia ranged between 2.30% and 2.71% and annual incidence between 0.31% and 0.39% during 2012-2016. In 2017, only states with the highest incidence and prevalence rates (KS, MS, MO) had data, resulting in higher prevalence (4.01%) and incidence (0.52%).” (opens the source at this quote in a new tab)CopyFlag

“The sample contained 328 records representing 493,006 noninstitutionalized civilian persons with schizophrenia. Eighty-seven percent had Medicaid or Medicare, 8% received care through the Veterans Health Administration, and 15% had private insurance for at least one day during the year. About 7% were uninsured all of the year.” (opens the source at this quote in a new tab)CopyFlag

“People with SSDs were less likely than people without SSDs to be uninsured (0.3% vs. 9.0%, AOR 0.02, CI=0.01–0.1). Coverage was predominantly by Medicaid (70.7%), Medicare (26.0%), or both (23.1%); 17.7% had private insurance.” (opens the source at this quote in a new tab)CopyFlag

“More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress.” (opens the source at this quote in a new tab)CopyFlag

“Projection analyses revealed the prevalence rate of schizophrenia in the U.S in 2022 was 0.45% (1.10% Medicare Fee-for-Service; 0.91% Medicaid, 1.10% Medicare Advantage, and 0.07% commercial), with an incidence rate of 0.08% (0.16% Medicare Fee-for-Service, 0.17% Medicaid, 0.17% Medicare Advantage, and 0.02% commercial).” (opens the source at this quote in a new tab)CopyFlag